Singapore, April 10 -- Leading Australian CRO Avance Clinical on 3 April 2020 detailed the top reasons it's APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback.

Avance Clinical is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise.

Avance Clinical said a primary reason that APAC biotechs chose Australia was the attractive Australian Government financial rebate of more than 40% on clinical trial spend.

Avance Clinical CEO Yvonne Lungershausen said this makes good financial sense for biotechs in early clinical phases.

Another key factor is that, during the current COVID-19 pandemic, sites can pivot to patient video visits or telemedicine, w...